Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system

José Miguel Rivera-Caravaca1,2*,†, Gregory Y. H. Lip2,3†, Vanessa Roldán4† and Francisco Marín5‡

1Faculty of Nursing, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), University of Murcia, Murcia, Spain, 2Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool Heart and Chest Hospital, Liverpool John Moores University, Liverpool, United Kingdom, 3Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, 4Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, University of Murica, Murcia, Spain,

†These authors share senior authorship
‡These authors share first authorship

KEYWORDS
atrial fibrillation, gastrointestinal system, oral anticoagulants, stroke, bleeding

The management of atrial fibrillation (AF), the most common cardiac arrhythmia, has evolved over the last years to be more multidisciplinary, comprehensive and integrated care based. This holistic view of the patient with AF is summed up as Atrial fibrillation Better Care (ABC) pathway (1), which is now recommended in many international guidelines (2–5).

This Research Topic of Frontiers in Cardiovascular Medicine includes three original articles, a mini-review and a case study which aim to shed light on some controversial and scarcely investigated topics in relation to the interaction of AF and the gastrointestinal system, and to explore novel approaches that should be considered for stroke prevention and risk-factor optimization.

Menichelli et al. investigated the relationship between circulating lipopolysaccharides (LPS) and antioxidant status in AF patients from the prospective, observational ATHERO-AF cohort. The authors measured gut-derived LPS and glutathione peroxidase 3 (GPx3), the blood isofrom of GPx involved in the detoxification of superoxide anion. In the multivariable Cox regression analysis, the group of patients with serum LPS levels above median and serum GPx3 levels below median, had and independently higher risk of cardiovascular events (adjusted HR 1.64, 95% CI 1.12–2.42), thus providing new evidence about the role of low-grade endotoxemia in favoring a pro-thrombotic phenotype in AF patients (6).
Wang et al. evaluated the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) compared to warfarin in AF patients with active, inactive and no peptic ulcer (PU) since patients with PU were excluded from the pivotal NOACs trials for stroke prevention because of the increased bleeding risk. Using a large cohort of patients from Taiwan who underwent esophagogastroduodenoscopy <1 year before anticoagulation, the authors investigated the risks of major bleeding, gastrointestinal bleeding, and ischemic stroke/systemic embolism (IS/SE). In summary, 2,955 patients were included. In either patients with active or inactive PU, there were not significant differences in the risk of adverse outcomes between NOACs and warfarin users. However, in AF patients free of PU, NOACs were associated with significantly lower risks of major bleeding (aHR 0.26, 95% CI 0.12–0.53), gastrointestinal bleeding (aHR 0.25, 95% CI 0.01–0.59), and the composite of major bleeding, IS/SE, or death (aHR 0.64, 95% CI 0.46–0.89). It can be concluded that NOACs were as effective as warfarin in preventing IS/SE irrespective of PU status and safer than warfarin in reducing major bleeding in AF patients with endoscopic findings of no PU (7). This study highlights the value of screening for PU status before starting OAC in AF patients.

Liao et al., aimed to analyze and compare the incidence of ischemic bowel disease (IBD) in AF patients receiving warfarin or NOACs in a Taiwan nationwide cohort including newly diagnosed patients with AF aged ≥20 years without IBD from 2012 to 2018. In 69,549 AF patients under OAC, the annual incidence of IBD was 0.036%, whereas the highest incidence was observed in patients with CHA2DS2-VASc ≥2 (0.039% per year). The risk of IBD was similar between the NOACs and warfarin groups (aHR 0.80, 95% CI 0.50–1.34) during the follow-up, and even a propensity score matching analysis showed the same results (HR 0.88, 95% CI 0.42–1.77). In a subgroup analysis comparing each NOAC against warfarin, dabigatran offered a trend towards lower risk of IBD (aHR 0.46, 95% CI 0.21–1.02, p = 0.057) (8). In summary, the annual incidence of IBD in AF patients taking OAC was low but presented a positive correlation with the increase of CHA2DS2-VASc score, and NOACs were comparable to warfarin in the risk of IBD.

In addition, Sánchez-Fuentes et al. performed a mini-review summarizing the current knowledge about drug-food/herbal products interactions of NOACs, and the potential implications of probiotics and prebiotics. In brief, this review demonstrated that there is still scarce evidence regarding this issue, but it should be considered that some herbs and food modulate P-gp and CYP3A4 activity hence their impact on the anticoagulant effect of NOACs cannot be neglected. On the other hand, novel therapies modifying gut microbiota composition and its activity such as probiotics and prebiotics might confer health benefits in users of NOACs, but the effect on the safety and efficacy on this family of anticoagulants is still unclear and warrants further research (9).

Finally, Cheng et al. presented a rare case of extensive submucosal esophageal hematoma developed after a Transcatheter aortic valve implantation (TAVI) procedure. This is a nice example of a rare complication of TAVI procedures. Some risk factors may increase the risk for esophageal hematoma, including abnormal hemostasis, inadequate manipulation of the TAVI device, and previous esophageal diseases. Hence, more data are required to determine the appropriate protocols for heparin dosing and monitoring during TAVI procedures, in order to prevent this complication. In addition, caution is recommended when selecting patients to undergo TAVI-assisted procedures to avoid TAVI-related esophageal hematoma, and a multidisciplinary approach is essential for devising the most effective strategies tailored to emergent cases (10).

This Research Topic clearly demonstrates that the management of AF should include a multidisciplinary approach, where different healthcare professionals provide their input on the appropriate care of AF patients. In this context, the interaction between the gastrointestinal system and AF requires particular attention and exploration.

Author contributions

JR-C and GL drafted the manuscript. VR and FM made a critical revision of the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

Author GL was consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. Author JR-C was consultant for Idorsia Pharmaceuticals Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. (2017) 14:627–8. doi: 10.1038/nrcardio.2017.153

2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. (2021) 42:373–498. doi: 10.1093/eurheartj/ehaa612

3. Lip GYH, Barjani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. (2018) 154:1121–201. doi: 10.1016/j.chest.2018.07.040

4. Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J. (2018) 48:1033–80. doi: 10.4070/kcj.2018.0339

5. Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. (2022) 122:20–47. doi: 10.1055/s-0041-1739411

6. Menichelli D, Carnevale R, Nocella C, Cammisotto V, Castellani V, Bartimoccia S, et al. Circulating lipopolysaccharides and impaired antioxidant status in patients with atrial fibrillation. Data from the ATHERO-AF study. Front Cardiovasc Med. (2021) 8:779503. doi: 10.3389/fcvm.2021.779503

7. Wang CL, Huang CH, Wu VC, Huang YC, Wang HS, Kuo CE, et al. Safety and effectiveness of direct oral anticoagulants vs. warfarin in patients with atrial fibrillation and endoscopy-diagnosed peptic ulcer. Front Cardiovasc Med. (2021) 8:774072. doi: 10.3389/fcvm.2021.774072

8. Liao JN, Chan YH, Kuo L, Tsai CT, Lim SS, Chao TF. Risk of ischemic bowel disease in patients with atrial fibrillation receiving warfarin or non-vitamin K antagonist oral anticoagulants. Front Cardiovasc Med. (2022) 9:874460. doi: 10.3389/fcvm.2022.874460

9. Sánchez-Fuentes A, Rivera-Caravaca JM, López-Gálvez R, Martín F, Roldán V. Non-vitamin K antagonist oral anticoagulants and drug-food interactions: implications for clinical practice and potential role of probiotics and prebiotics. Front Cardiovasc Med. (2021) 8:787235. doi: 10.3389/fcvm.2021.787235

10. Cheng C, Zhou Y, Wang Y, Shi L, Tian Y, Liu X. Treatment of esophageal hematoma after left atrial appendage occlusion: a case report. Front Cardiovasc Med. (2022) 9:941924. doi: 10.3389/fcvm.2022.941924